Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05512234

Effect of Probiotic Limosilactobacillus Reuteri (L. Reuteri) on Crying Time in Infants With Colic

A Double-blind, Mylti-center, Randomised, Placebo-controlled, Parallel-group Study Evaluating the Effect of Probiotic Limosilactobacillus Reuteri (L. Reuteri) on Crying and Fussing Time in Infants With Colic

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
102 (estimated)
Sponsor
BioGaia AB · Industry
Sex
All
Age
3 Weeks – 8 Weeks
Healthy volunteers
Not accepted

Summary

This is a double-blind, multi-center, randomized, placebo-controlled, parallel-group study in infants with colic with the primary objective to evaluate crying time.

Detailed description

Prevalence of infantile colic varies according to the definition used but estimates range between 5 % and 26 % of the infant population. To differentiate colic from other, more serious conditions it should be characterized by several clinical features. Infant colic is often accompanied by flushing the face, frown, tensing of the abdomen, clenching of the fists, and drawing up the leg, frequent, prolonged, and intense crying or fussiness in a healthy infant. Even though infant colic is benign and usually self-limiting condition it is a source of major distress for the infant, parents, family, and health care givers. Despite infant colic occurs frequently, little agreement has been reached on the definition, pathogenesis, or the optimal management strategy for infant colic. Recent systematic reviews and meta-analyses showed that probiotic L. reuteri DSM 17938 supplementation significantly lowered the number of hours of crying and fussing daily. A significant peak effect was seen at 3 weeks in most studies. Interestingly, babies with infant colic were found to have increased evidence of gut inflammation, as evidenced by high levels of the antimicrobial peptide fecal calprotectin; also, the levels of fecal calprotectin declined significantly as the condition resolved.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTL. reuteriDietary supplementation with drops containing L. reuteri once daily for 21 consecutive days
DIETARY_SUPPLEMENTPlaceboDietary supplementation with placebo drops identical to those containing L. reuteri once daily for 21 consecutive days

Timeline

Start date
2022-07-13
Primary completion
2025-10-30
Completion
2025-10-30
First posted
2022-08-23
Last updated
2025-09-22

Locations

2 sites across 2 countries: Ireland, Sweden

Source: ClinicalTrials.gov record NCT05512234. Inclusion in this directory is not an endorsement.